• Sat. Jul 31st, 2021

mccoy.ventures

All content has been processed with publicly available content spinners. Not for human consumption.

US approves first new Alzheimer’s drug in 20 years

In March 2019, late-stage international trials of aducanumab, involving about 3,000 patients, were halted when analysis showed the drug, given as a monthly infusion, was not better at slowing the deterioration of memory and thinking problems than a dummy drug.